MannKind Expands Executive Leadership Team
MannKind (MNKD) has appointed Dominic Marasco, RPh, as President of its Endocrine Business Unit, effective January 6, 2025. Marasco, who brings over 25 years of experience in biopharma and biotech sectors, will report to CEO Michael Castagna.
Marasco's most recent role was Executive President and Chief Commercial Officer at Envision Pharma Group, where he led technology and AI business units. His prior experience includes leadership positions at BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals, and Eli Lilly. He holds a degree from the Philadelphia College of Pharmacy and completed Harvard Business School's Advanced Management Program.
The appointment aims to leverage Marasco's global experience to build upon Afrezza's positive clinical trial results and drive strategic growth in the company's endocrine business.
MannKind (MNKD) ha nominato Dominic Marasco, RPh, come Presidente della sua Unità Aziendale Endocrina, a partire dal 6 gennaio 2025. Marasco, che porta con sé oltre 25 anni di esperienza nei settori della biopharma e biotech, riporterà al CEO Michael Castagna.
Il ruolo più recente di Marasco è stato quello di Presidente Esecutivo e Chief Commercial Officer presso Envision Pharma Group, dove ha guidato le unità di business tecnologico e AI. La sua esperienza precedente include posizioni di leadership presso BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals ed Eli Lilly. Possiede una laurea dal Philadelphia College of Pharmacy e ha completato il Programma di Management Avanzato della Harvard Business School.
La nomina mira a sfruttare l'esperienza globale di Marasco per costruire sui risultati positivi degli studi clinici di Afrezza e promuovere la crescita strategica del business endocrino dell'azienda.
MannKind (MNKD) ha nombrado a Dominic Marasco, RPh, como Presidente de su Unidad de Negocios Endocrinos, con efecto a partir del 6 de enero de 2025. Marasco, que aporta más de 25 años de experiencia en los sectores biopharma y biotech, reportará al CEO Michael Castagna.
El cargo más reciente de Marasco fue Presidente Ejecutivo y Director Comercial en Envision Pharma Group, donde lideró las unidades de negocio de tecnología y IA. Su experiencia previa incluye puestos de liderazgo en BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals y Eli Lilly. Tiene un título del Philadelphia College of Pharmacy y completó el Programa de Gestión Avanzada de Harvard Business School.
La designación busca aprovechar la experiencia global de Marasco para construir sobre los resultados positivos de los ensayos clínicos de Afrezza y impulsar el crecimiento estratégico en el negocio endocrino de la empresa.
MannKind (MNKD)는 Dominic Marasco, RPh를 2025년 1월 6일자로 내분비 비즈니스 유닛의 사장으로 임명했습니다. Marasco는 25년 이상의 바이오 제약 및 생명공학 분야 경험을 가지고 있으며, CEO인 Michael Castagna에게 보고할 것입니다.
Marasco의 최근 역할은 Envision Pharma Group의 집행 회장 및 최고 상업 책임자였으며, 그곳에서 기술 및 AI 비즈니스 유닛을 이끌었습니다. 이전에는 BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals 및 Eli Lilly에서 리더십 직책을 역임하였습니다. 그는 필라델피아 약학대학에서 학위를 받았고 하버드 비즈니스 스쿨의 고급 관리 프로그램을 수료했습니다.
이번 임명은 Marasco의 글로벌 경험을 활용하여 Afrezza의 긍정적인 임상 시험 결과를 기반으로 하고 회사의 내분비 사업에서 전략적 성장을 촉진하는 것을 목표로 합니다.
MannKind (MNKD) a nommé Dominic Marasco, RPh président de son unité commerciale endocrinienne, à compter du 6 janvier 2025. Marasco, qui apporte plus de 25 ans d'expérience dans les secteurs biopharma et biotechnologie, rendra compte au PDG Michael Castagna.
Le dernier poste de Marasco était celui de président exécutif et directeur commercial chez Envision Pharma Group, où il a dirigé les unités commerciales technologiques et IA. Son expérience précédente comprend des postes de direction chez BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals et Eli Lilly. Il est diplômé du Philadelphia College of Pharmacy et a terminé le programme de management avancé de la Harvard Business School.
Cette nomination vise à tirer parti de l'expérience mondiale de Marasco pour s'appuyer sur les résultats positifs des essais cliniques d'Afrezza et favoriser la croissance stratégique de l'entreprise dans le domaine endocrinien.
MannKind (MNKD) hat Dominic Marasco, RPh zum Präsidenten seiner Endokrinen Geschäftseinheit ernannt, mit Wirkung zum 6. Januar 2025. Marasco, der über 25 Jahre Erfahrung in den Bereichen Biopharma und Biotechnologie verfügt, wird an den CEO Michael Castagna berichten.
Marascos letzte Position war Executive President und Chief Commercial Officer bei Envision Pharma Group, wo er die Technologie- und KI-Geschäftseinheiten leitet. Zuvor hatte er Führungspositionen bei BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals und Eli Lilly inne. Er hat einen Abschluss vom Philadelphia College of Pharmacy und hat das Programm für Fortgeschrittenes Management der Harvard Business School abgeschlossen.
Die Ernennung zielt darauf ab, Marascos globale Erfahrung zu nutzen, um auf den positiven Ergebnissen von Afrezza klinischen Studien aufzubauen und das strategische Wachstum im Endokrinen Geschäftsbereich des Unternehmens voranzutreiben.
- Strategic hire with extensive commercial leadership experience in biopharma
- Addition of executive with proven track record in driving strategic growth
- Strengthening of leadership team with expertise in global markets
- None.
- Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.
Mr. Marasco is a member of MannKind’s executive leadership team and reports to Michael Castagna, PharmD, Chief Executive Officer. “Dominic is an innovative leader recognized for driving strategic growth and operational excellence that will be transformative for our Endocrine Business Unit,” said Dr. Castagna. “As we continue to build upon the positive clinical trial readouts for Afrezza, Dominic’s global experience will be instrumental to our company’s future.”
Mr. Marasco joins MannKind with an accomplished track record of more than 25 years of driving commercial success in the biopharma and biotech sectors. He recently held the position of Executive President, Chief Commercial Officer for Envision Pharma Group, leading its technology and artificial intelligence business units and all commercial operations. Before joining Envision Pharma in February 2023, Mr. Marasco was Chief Commercial Officer at BioAgilytix Labs, Inc. from December 2019 until December 2022.
Prior to BioAgilytix, he was EVP, Global Business Development, Commercial Group at Syneos Health after serving in progressive leadership roles at Amgen, Inc. including Head of U.S. Sales for the Neuroscience Business Unit and before that Global Commercial Head, Amgen Biosimilars. Mr. Marasco also held successful commercial leadership roles at Sandoz Biopharmaceuticals, a Novartis Company, and Quintiles Transnational Holdings Inc (now IQVIA).
He began his career as a pharmacist before joining Eli Lilly and Company in a sales capacity. Mr. Marasco is a graduate of the Philadelphia College of Pharmacy and an alumnus of the Harvard Business School’s Advanced Management Program.
“The energy behind Afrezza and the momentum of MannKind’s pipeline is inspiring,” said Marasco. “I am excited to work with an innovative team that continues to push the boundaries of what’s possible in endocrine care and help more patients worldwide.”
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
Forward-Looking Statements
This press release contains forward-looking statements about the potential transformation of a business unit that involves risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the products we are commercializing may only achieve a limited degree of commercial success, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MANNKIND is a registered trademark of MannKind Corporation.
FAQ
When will Dominic Marasco start as President of MNKD's Endocrine Business Unit?
What is Dominic Marasco's most recent position before joining MNKD?
How many years of experience does MNKD's new Endocrine Business Unit President have?
What is the strategic importance of Marasco's appointment for MNKD's Afrezza development?
